|Adverse reactions usually occur in the first eight weeks of treatment. The most common minor reactions are nausea, headache, arthralgia, mild gastrointestinal disturbance, skin rashes and pruritus. These reactions are usually self-limiting and may not require withdrawal of the drug.|
Blood and lymphatic system disordersBone marrow depression including neutropenia, eosinophilia, leucopenia, agranulocytosis has been reported. Fatalities with carbimazole-induced agranulocytosis have been reported.Rare cases of pancytopenia/aplastic anaemia and isolated thrombocytopenia have also been reported. Additionally, very rare cases of haemolytic anaemia have been reported. Patients should always be warned about the onset of sore throats, bruising or bleeding, mouth ulcers, fever, malaise and should be instructed to stop the drug and to seek medical advice immediately. In such patients, white blood cell counts should be performed immediately particularly where there is any clinical evidence of infection.
Nervous system disordersHeadache
Gastrointestinal system disordersNausea, mild gastrointestinal disturbance.Loss of sense of taste has been observed.
General disorders and administration site conditionsFever, MalaiseHepato-biliary system disordersHepatic disorders, including abnormal liver function tests, hepatitis, cholestatic hepatitis, cholestatic jaundice and most commonly jaundice, have been reported; in these cases carbimazole tablets should be withdrawn.
Injury, poisoning and procedural complicationsBruising
Skin and subcutaneous tissue disordersSkin rashes, pruritus, urticaria. Hair loss has been occasionally reported.
Musculoskeletal system disordersIsolated cases of myopathy have been reported. Patients experiencing myalgia after the intake of Carbimazole should have their creatine phosphokinase levels monitored.
Hypersensitivity and allergic reactionAngioedema and multi-system hypersensitivity reactions such as cutaneous vasculitis, liver, lung and renal effects occur.